Ghana-based Center for Pharmaceutical Advancement and Training (Cepat), a piece of the U.s. Pharmacopeial Convention's (USP) Global Health Impact Program, is presently utilizing anti-counterfeiting technology in its battle to recognize fake anti-malaria drugs, a real issue in Ghana and Sub-Saharan Africa.
Thermo Scientific Truscan instruments are perfect for the Cepat exertion due to their streamlined client interface, simplicity of execution and inalienable specificity, intended to permit key work force at the purpose of need to rapidly and faultlessly recognize fake medications.
Get detailed report at: http://www.reportsandintelligence.com/anti-counterfeit-market
“Malaria is a major health issue in this region and anti-malarial drugs are critical to survival,” said Dr. Patrick Lukulay, vice president at USP in charge of the Promoting Quality of Medicines program.
“Sadly, counterfeiters are exploiting this need and attempting to capitalize, and we need ways to stay ahead of them. Because TruScan is easy to learn and delivers immediate results, we’re able to make it an integral part of our ongoing effort to safeguard the public and improve human health.”
We’re pleased to play a role in a very important public health issue,” said Bob Brush, business development manager at Thermo Fisher Scientific. “The work CePAT is doing is precisely what we designed TruScan to do, make it easy to confirm that a substance – whether it’s a pill, powder or liquid and even if it’s already packaged and shipped – is what it says it is.”
Anti-Counterfeiting is increasingly becoming important as a result of increased product duplication. As per Reports and Intelligence, the Anti-Counterfeiting market would reach a market value of 142.7 billion by 2020.